TLR7 and TLR9-directed plasma cell formation: Dissecting the molecular basis for their differential dependence on IFN-induced signals
TLR7 and TLR9-directed plasma cell formation: Dissecting the molecular basis for their differential dependence on IFN-induced signals
批准号:
10642784
负责人:
Frances E. Lund
金额:
$71.33万
依托单位国家:
美国
项目类别:
财政年份:
2020
资助国家:
美国
项目状态:
未结题
起止时间:
2020-07-10 至 2025-06-30
关键词:
Activated B-LymphocyteAddressAdjuvantAffectAmericanAntibodiesAntibody ResponseAntigensAutoantigensAutoimmuneAutoimmune DiseasesAutoimmunityAutomobile DrivingB cell differentiationB-Cell ActivationB-Lymphocyte SubsetsB-LymphocytesBindingBiological ModelsCell Differentiation processCellsChromatinClinicalDataDependenceDevelopmentDiseaseEffector CellFDA approvedFinancial HardshipFutureGene Expression RegulationGenesGenetic TranscriptionGoalsHealthHumanIRF1 geneImmune responseImmune systemImmunoglobulin-Secreting CellsIndividualInflammation MediatorsInflammatoryInterferon Type IIInterferon alphaInterferonsInterleukin-2InterventionJAK1 geneKnowledgeLearningLicensingLigandsMaintenanceMediatingMediatorMolecularMolecular ProbesNuclear TranslocationNucleic Acid Regulatory SequencesOrganPathogenicityPathway interactionsPatientsPharmaceutical PreparationsPlasma CellsPlayProcessProductionRefractoryResearchRheumatoid ArthritisRoleSeverity of illnessSignal InductionSignal PathwaySignal TransductionSqualeneStudy modelsSystemic Lupus ErythematosusSystemic TherapyTLR7 geneTestingTherapeutic InterventionTimeTissuesTranscription Factor AP-1Up-RegulationVaccine AntigenVaccinescytokinedirected differentiationepigenomeexperimental studyinhibitorinterleukin-21mouse modelnovel therapeuticspathogenpreventprogramsresponsesupport networktranscription factortranscriptome
中文摘要
自身免疫性疾病,如风湿性关节炎(RA)或系统性红斑狼疮(SLE),
这是一个巨大的经济负担,也是一个巨大的负担。由于许多个体对用本发明的药物治疗是难治的,
虽然现有药物的治疗效果不佳,但对于开发用于这些患者的新疗法存在很大的未满足需求。虽然我们知道
B细胞、抗体(Ab)分泌细胞(ASCs)、炎性细胞因子和TLR配体都发挥重要作用,
尽管我们在驱动对病原体、疫苗和自身抗原的体液免疫应答中发挥着重要作用,但我们仍然缺乏一个基本的
了解细胞因子和TLR配体提供的信号如何通过应答B细胞整合,
促进ASCs的发展和扩张,在自身免疫的情况下,ASCs可产生致病性
autoAbs.我们描述了一种不寻常的B细胞亚群(DN 2细胞),这种细胞存在于健康供体(HD)中。
在部分SLE和RA患者中扩增。我们发现,与疾病严重程度相关的DN 2细胞
在SLE中,可以迅速分化为ASC,表明这些细胞是“稳定的”前ASC。我们的数据表明
IFNg提供的早期信号控制SLE患者和HD中DN 2的发展。此外,离体
使用SLE患者DN 2细胞的实验揭示了这些IFNg-“致敏的”前ASC的分化需要
我们观察到由TLR 7配体和IL-21提供的额外信号,
控制人B细胞的TLR 7依赖性而非TLR 9依赖性分化。我们证明了IFNg,但没有
IFN α诱导人B细胞中转录因子IRF 1的表达,IRF 1促进TLR 7驱动的
人ASC形成。因此,我们确定了至少2种,可能3种,独立的B细胞分化
这些途径差异依赖于IFN、IFN诱导的转录因子和TLR配体。至今没有
研究集中在IFNg如何调节B细胞分化以及为什么B细胞响应于IFNg而分化。
TLR 7和TLR 9对IFNg的依赖性不同。在这个提议中,我们将检验我们的中心假设,
IFNg选择性诱导B细胞的IRF 1依赖性重编程,从而允许这些细胞分化
对参与TLR 7信号网络的(自身)抗原作出反应。这项建议的近期目标是
(i)检查IFNg和IFNa在促进TLR 7依赖性免疫应答中发挥的重叠和不同的作用,
人ASC发育;(ii)确定IRF 1如何支持B细胞分化和(iii)评估TLR 7-
介导的B细胞分化依赖于IFN衍生的信号。我们的长期目标是利用我们所学到的
控制TLR和苦参碱诱导的B细胞分化的基本机制,以确定干预措施
可以调节健康和疾病中ASCs的形成,维持或功能。本研究是
重要的是,因为我们将首次定义IFN依赖性TLR 7驱动的
人B细胞分化。我们相信,我们的研究是重要的,因为它们将促进我们的基本
了解控制人类B细胞分化的机制,并可能在未来允许选择性地
靶向TLR 7驱动的自身抗体应答而不影响B细胞对其它类型抗原的应答。
!
英文摘要
Autoimmune disease like Rheumatoid Arthritis (RA) or Systemic Lupus Erythematosus (SLE) cause significant
suffering and represent a huge financial burden. Since many individuals are refractory to treatment with the
available drugs, there is a large unmet need to develop new therapeutics for these patients. Although we know
that B cells, antibody (Ab) secreting cells (ASCs), inflammatory cytokines and TLR ligands all play important
roles in driving humoral immune responses to pathogens, vaccines and self-antigens, we still lack a fundamental
understanding of how the signals provided by cytokines and TLR ligands are integrated by responding B cells to
promote the development and expansion of ASCs, which in the case of autoimmunity may produce pathogenic
autoAbs. We characterized an unusual subset of B cells (DN2 cells), which are found in healthy donors (HD)
and expanded in some SLE and RA patients. We showed that DN2 cells, which correlate with disease severity
in SLE, can rapidly differentiate into ASCs, suggesting that these cells are “poised” pre-ASCs. Our data suggest
that early signals provided by IFNg control DN2 development in SLE patients and HD. Moreover, ex vivo
experiments using SLE patient DN2 cells reveal that differentiation of these IFNg-“primed” pre-ASCs requires
additional signals provided by TLR7 ligands and IL-21 and we observed that signals provided by IFNg and IFNa
control TLR7-dependent but not TLR9-dependent differentiation of human B cells. We showed that IFNg but not
IFNa induces expression of the transcription factor IRF1 in human B cells and that IRF1 promotes TLR7-driven
human ASC formation. Therefore, we identified at least 2, and likely 3, independent B cell differentiation
pathways that are differentially reliant on IFNs, IFN-induced transcription factors and TLR ligands. To date, no
studies have focused on how IFNg regulates B cell differentiation and why B cell differentiation in response to
TLR7 and TLR9 are differentially dependent on IFNg. In this proposal, we will test our central hypothesis that
IFNg selectively induces IRF1-dependent reprogramming of B cells, thereby licensing these cells to differentiate
in response to (auto)antigens that engage the TLR7 signaling network. The immediate objectives of this proposal
are to (i) examine the overlapping and distinct roles that IFNg and IFNa play in promoting TLR7-dependent
human ASC development; (ii) determine how IRF1 supports B cell differentiation and (iii) evaluate why TLR7-
mediated B cell differentiation is reliant on IFN-derived signals. Our long-term goal is to use what we learn about
the fundamental mechanisms controlling TLR and cytokine-induced B cell differentiation to identify interventions
that can regulate the formation, maintenance or function of ASCs in health and disease. This research is
significant because we will, for the first time, define the mechanistic basis for IFNg-dependent TLR7-driven
human B cell differentiation. We believe that our studies are important as they will advance our fundamental
understanding of the mechanisms controlling human B cell differentiation and may in the future allow selective
targeting of TLR7-driven autoAb responses without affecting B cell responses to other types of antigens.
!
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
TLR7 and TLR9-directed plasma cell formation: Dissecting the molecular basis for their differential dependence on IFN-induced signals
-
批准号:10431929
-
项目类别:
-
资助金额:$71.33万
-
财政年份:2020
-
负责人:Frances E. Lund
-
依托单位:
Tissue and organ specific human B cell immunity
-
批准号:10265689
-
项目类别:
-
资助金额:$44.49万
-
财政年份:2020
-
负责人:Frances E. Lund
-
依托单位:
TLR7 and TLR9-directed plasma cell formation: Dissecting the molecular basis for their differential dependence on IFN-induced signals
-
批准号:10032785
-
项目类别:
-
资助金额:$72.54万
-
财政年份:2020
-
负责人:Frances E. Lund
-
依托单位:
Identification and characterization of effector memory B cell populations that dominate memory responses to subsequent influenza infection and vaccination
-
批准号:10227903
-
项目类别:
-
资助金额:$73.54万
-
财政年份:2020
-
负责人:Frances E. Lund
-
依托单位:
Identification and characterization of effector memory B cell populations that dominate memory responses to subsequent influenza infection and vaccination
-
批准号:10455632
-
项目类别:
-
资助金额:$73.54万
-
财政年份:2020
-
负责人:Frances E. Lund
-
依托单位:
TLR7 and TLR9-directed plasma cell formation: Dissecting the molecular basis for their differential dependence on IFN-induced signals
-
批准号:10214491
-
项目类别:
-
资助金额:$71.33万
-
财政年份:2020
-
负责人:Frances E. Lund
-
依托单位:
Administrative Core
-
批准号:10395996
-
项目类别:
-
资助金额:$44.45万
-
财政年份:2019
-
负责人:Frances E. Lund
-
依托单位:
Characterization of virus-specific human B cell subsets in lymphoid and non-lymphoid tissues
-
批准号:10592418
-
项目类别:
-
资助金额:$94.58万
-
财政年份:2019
-
负责人:Frances E. Lund
-
依托单位:
Tissue and organ specific human B cell immunity
-
批准号:10592408
-
项目类别:
-
资助金额:$355.3万
-
财政年份:2019
-
负责人:Frances E. Lund
-
依托单位:
Administrative Core
-
批准号:10592409
-
项目类别:
-
资助金额:$9.93万
-
财政年份:2019
-
负责人:Frances E. Lund
-
依托单位:
Infrastructure and Opportunity Fund Management Core
-
批准号:10592414
-
项目类别:
-
资助金额:$145.47万
-
财政年份:2019
-
负责人:Frances E. Lund
-
依托单位:
Characterization of virus-specific human B cell subsets in lymphoid and non-lymphoid tissues
-
批准号:10396002
-
项目类别:
-
资助金额:$44.45万
-
财政年份:2019
-
负责人:Frances E. Lund
-
依托单位:
Tissue and organ specific human B cell immunity
-
批准号:10395994
-
项目类别:
-
资助金额:$355.62万
-
财政年份:2019
-
负责人:Frances E. Lund
-
依托单位:
Infrastructure and Opportunity Fund Management Core
-
批准号:10396000
-
项目类别:
-
资助金额:$44.45万
-
财政年份:2019
-
负责人:Frances E. Lund
-
依托单位:
Control of anti-viral B cell responses by IFNg, T-bet and Eomes
-
批准号:8806524
-
项目类别:
-
资助金额:$21.45万
-
财政年份:2014
-
负责人:Frances E. Lund
-
依托单位:
Control of B cell differentiation by IFNg induced transcription factors
-
批准号:10307593
-
项目类别:
-
资助金额:$26.0万
-
财政年份:2014
-
负责人:Frances E. Lund
-
依托单位:
Control of B cell differentiation by IFNg induced transcription factors
-
批准号:10521294
-
项目类别:
-
资助金额:$26.0万
-
财政年份:2014
-
负责人:Frances E. Lund
-
依托单位:
Control of anti-viral B cell responses by IFNg, T-bet and Eomes
-
批准号:8992350
-
项目类别:
-
资助金额:$21.45万
-
财政年份:2014
-
负责人:Frances E. Lund
-
依托单位:
Control of B cell differentiation by IFNg induced transcription factors
-
批准号:9887750
-
项目类别:
-
资助金额:$26.0万
-
财政年份:2014
-
负责人:Frances E. Lund
-
依托单位:
Control of anti-viral B cell responses by IFNg, T-bet and Eomes
-
批准号:9204378
-
项目类别:
-
资助金额:$21.45万
-
财政年份:2014
-
负责人:Frances E. Lund
-
依托单位:
海外基金